NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹101 Cr | ₹135 Cr | ₹143 Cr | ₹118 Cr | ₹83 Cr |
What is the latest Total Non-Current Liabilities ratio of NATCO PHARMA ?
Year | Total Non-Current Liabilities |
---|---|
Mar2023 | ₹101 Cr |
Mar2022 | ₹135 Cr |
Mar2021 | ₹143 Cr |
Mar2020 | ₹118 Cr |
Mar2019 | ₹83 Cr |
How is Total Non-Current Liabilities of NATCO PHARMA Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹101 Cr | -25.61 | |
Mar2022 | ₹135 Cr | -5.46 | |
Mar2021 | ₹143 Cr | 21.31 | |
Mar2020 | ₹118 Cr | 41.25 | |
Mar2019 | ₹83 Cr | - |
Compare Total Non-Current Liabilities of peers of NATCO PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATCO PHARMA | ₹18,107.0 Cr | -1.1% | 6.3% | 78.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹364,315.0 Cr | -0.1% | -6.3% | 53.5% | Stock Analytics | |
CIPLA | ₹114,614.0 Cr | 1% | -5% | 53.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹105,233.0 Cr | 3.2% | 15.3% | 23.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹104,900.0 Cr | 1.1% | 2.2% | 26% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹99,426.0 Cr | 3.9% | -1.7% | 85.2% | Stock Analytics |
NATCO PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATCO PHARMA | -1.1% |
6.3% |
78.3% |
SENSEX | 1% |
2.2% |
23.7% |
You may also like the below Video Courses